About this webinar
Public health is a topic of importance for all countries around the world. The COVID-19 pandemic has exposed weaknesses in health care systems, including those in the Heartland Region of the US. Despite its negatives, the pandemic has also inspired those who have power, to employ new tactics to better healthcare systems globally.
In this event, we have invited industry leaders, practitioners, and experts in the field of public health to share their thoughts on the industry’s future. Our experts from both Chinese and American backgrounds will share their thoughts on how each country may or may not be successfully utilizing and supporting their systems and methods to improve them. Our panelists will share their opinions on how global collaboration can improve healthcare and be beneficial to all.
This event is part of USHCA’s ongoing series, The Way Forward, where we discuss different ideas and initiatives used by the US and China and how they can be applied to the Heartland region.
Zunyou Wu, MD, Ph.D 吴尊友
Chief Epidemiologist, China CDC
Adjunct Professor of Epidemiology, UCLA
Zunyou Wu 吴尊友
Dr. Wu has worked in infectious disease control for over 30 years, has published over 500 academic papers, and 261 of them in SCI journals, including Science, Lancet, JAMA. He has received many honors including the 2005 International Rolleston Award for implementing harm reduction in China, “Hall of Fame” of 2006 UCLA School of Public Health's Alumni, UNAIDS Gold Medal in 2008, and many awards from Chinese government. Dr. Wu was actively involved in response to the SARS outbreak in Beijing in 2003, and is currently actively involved in response to COVID-19 in China.
Dr. Wu is now a member of UNAIDS Scientific Expert Panel, and UNAIDS Evaluation Expert Advisory Committee. Dr. Wu has worked on SARS in 2003 and was an expert in China’s delegation attending 56th World Health Assembly leading by Vice Premier Wu Yi. He joined efforts in controlling CoVID-19 since January 2020. Dr. Wu is a member of WHO-China join mission in February 16-24, 2020.
Sept.1985-Jul.1988 Research Assistant and Teaching Assistant, Department of Epidemiology, School of Public Health, Anhui Medical University, Hefei, Anhui, China.
Aug.1988-Sep.1991 Epidemiologist, Department of Epidemiology, Anhui Anti-Epidemic Station, Hefei, Anhui, China
Jun.1992-Jan.1994 Research Assistant, Department of Immunology and Department of Epidemiology, University of California, Los Angeles, CA, USA.
Jul.1995-Jun.1997 Postdoctoral Fellow, Center for HIV/AIDS Surveillance and Control, Chinese Academy of Preventive Medicine (CAPM), Beijing, China
Mar.1996-Mar.1999 Research Associate, Center for HIV/AIDS Surveillance and Control, CAPM, Beijing, China
Jul.1997-Dec.1998 Deputy Chief, Intervention Sector, National Center for AIDS Prevention and Control, CAPM, Beijing, China
Jan.1999-Jan.2002 Director, Department of Behavioral Intervention, National Center for AIDS Prevention and Control, CAPM, Beijing, China
Jan. 2002-Present Director, Division of Health Education and Intervention, National Center for AIDS/STC Control and Prevention (NCAIDS), Chinese Center for Disease Control and Prevention (China CDC), Beijing, China.
Oct.2005-Apr.2017 Director, NCAIDS/China CDC
Jul. 2009- Present Adjunct Professor of Epidemiology, UCLA School of Public Health
Apr. 2017-Present Chief Epidemiologist China CDC
Dr. Yang Gonghuan 杨功焕
Professor, Institute of Basic Medical Sciences at Peking Union Medical College. Vice Director of China CDC from 2005-2011
Dr. Yang Gonghuan 杨功焕
Dr. Yang Gonghuan ( 杨功焕), an expert on the epidemiology of non-communicable diseases (NCDs) in China, is the leader of a recent China Global Burden of Disease Study. Previously serving as vice director of China CDC from 2005-2011, Yang is currently Professor at the Institute of Basic Medical Sciences at Peking Union Medical College, Director of the Global Smoking Research Center, and Director of the China Burden of Disease Research and Dissemination Center where her research focuses primarily on national disease surveillance and tobacco control. Yang earned her degree in medicine from West-China Medical University and studied public health at Harvard University.
Bruce Y. Lee
Professor of Health Policy and Management - CUNY
Executive Director, PHICOR (Public Health Informatics Computational Operations Research)
Bruce Y. Lee
Bruce Y. Lee, MD, MBA has expertise in systems modeling, computational and digital health, entrepreneurship, and science and health journalism and communications. He is a Professor of Health Policy and Management at the City University of New York (CUNY) Graduate School of Public Health & Health Policy where he is the Executive Director of PHICOR (Public Health Computational and Operations Research). He has over two decades experience in industry and academia developing mathematical and computational models to assist a wide range of decision makers in health and public health. This has included serving as an Associate Professor at the Johns Hopkins School of Public Health and the Carey Business School, Associate Professor at the University of Pittsburgh, and Senior Manager at Quintiles Transnational. Other experience includes working in equity research at Montgomery Securities and founding two companies. He has authored over 200 scientific publications (including over 100 first author and over 65 last author).
Dr. Lee has written extensively for the general media. He is a Senior Contributor for Forbes, covering a wide range of health-related topics and having written over 700 articles. His writing has also been featured in a number of other media outlets including Time, The Guardian, the HuffPost, and the MIT Technology Review. His work and expertise have appeared in leading media outlets such as the New York Times, USA Today, the Los Angeles Times, Newsweek, CBS News, Businessweek, U.S. News and World Report, Bloomberg News, Reuters, and National Public Radio (NPR).
MBA in from Stanford Graduate School of Business, Stanford, CA
MD in from Harvard Medical School, Boston, MA
BA in from Harvard University, Cambridge, MA
Systems science, computational modeling, digital health, science and health communications, social entrepreneurship
PHICOR (Public Health Informatics Computational Operations Research)
Professor Vivian Lin
Executive Associate Dean, Professor of Public Health Practices - LKS Faculty of Medicine at the University of Hong Kong
Professor Vivian Lin joined the LKS Faculty of Medicine as Executive Associate Dean in March 2019. She is concurrently Professor of Public Health Practice. She has more than 30 years of experience in public health, with a variety of leading roles in policy and programme development, health services planning, research and teaching, and senior administration in complex organizations.
Vivian was Chair of Public Health from 2000-2013 at La Trobe University in Melbourne before serving the WHO as Director of Health Systems in the Western Pacific Regional Office for 2013-2018, where she led on the global priorities of universal health coverage and sustainable development goals, cross-cutting priority issues of antimicrobial resistance, ageing, and gender-based violence, and on health system development issues including health financing, health law and ethics, health workforce, traditional medicines, service delivery, and health information systems.
Vivian has also worked at senior executive level in health policy in several Australian jurisdictions, including as Executive Officer of the National Public Health Partnership. She has also consulted widely for the World Bank, UK Department for International Development, Australian Agency for International Development, World Health Organization, and various Australian governments at state and federal levels. In these roles, she has developed the first Australian health sector aid strategy for China, the WHO framework for people-centred health care for the Western Pacific Region, and the ASEAN Healthy Lifestyle Strategy. She was commissioned to undertake major studies of indicators used globally for gender equity and health, on risks and regulatory requirements for naturopathy, and evaluation of health promotion leadership program.
Vivian has served on multiple academic, government and community boards. She was Vice President for Scientific Affairs for the International Union for Health Promotion and Education in 2007-2013, chair of Australian National Network of Academic Public Health Institutions for 2006-2008, member of the public health committee of the Australian Medical Association for 2003-2006, policy convenor for the Public Health Association of Australia in 1995-2001, and board member of the Cooperative Research Centre for Aboriginal Health for 2003-2009. As ministerial appointee, she was the inaugural president of the Chinese Medicine Registration Board of Victoria serving between 2000-2009, member of the Australia-China Council 2006-2009, and member of the Diary Food Safety Board of Victoria for 2000-2003.
Vivian is the author of several leading textbooks in Australia on health policy and planning, as well as on China. She has served on multiple editorial boards for leading journals, including as health policy editor for Social Science and Medicine. Most recently, she was a member of the International Panel on Social Progress and chaired its health cross-cutting group. She has served on the medicine and public health panel for the New Zealand Tertiary Commission’s Performance-based Research Funding exercise on 5 occasions between 2003 and 2018.
Vivian earned her BA from Yale University and MPH and DrPH from UC Berkeley. She was a recipient of the Drotman Award by the American Public Health Association in 1982 which recognizes promising young public health professional.
Lin V, Smith J and Fawkes S. PUBLIC HEALTH PRACTICE IN AUSTRALIA: THE ORGANISED EFFORT. Allen and Unwin, Sydney. 2007. 2nd edition 2014.
McQueen, Wismar M, Lin V, Jones C, and Davies M. (Eds) INTERSECTORAL GOVERNANCE FOR HEALTH IN ALL POLICIES. European Observatory For Health Systems And Policy. 2012.
Lin V, Guo Y, Legge D, and Wu QH. (Eds). HEALTH POLICY IN TRANSITION: FOR AND OF CHINA. Peking University Medical Press. 2010.
Lin V and Gibson B (Eds). EVIDENCE-BASED HEALTH POLICY: PROBLEMS AND POSSIBILITIES, Oxford University Press, Melbourne, 2003.
Garrett P, Eagar K, and Lin V, HEALTH PLANNING: AUSTRALIAN PERSPECTIVES, Allen and Unwin, Sydney. 2001.
Book Chapters and Articles
Lin V, Carter B, and Guo Y. Policy, Research, and Behavioral Medicine. In Fisher, E. B., Cameron, L. D., Christensen, A. J., Ehlert, U., Guo, Y., Oldenburg, B., & Snoek, F. J. (Eds.). (2016). Principles and Concepts of Behavioral Medicine: A Global Handbook. New York: Springer. 2017.
Lin V and de Leeuw E. Environments for Health – a Governance Challenge in DeLeeuw E and Simos J (Eds). Healthy Cities: The Theory, Policy and Practice of Value-based Urban Health Planning. Springer. 2017.
Kieny MP, Bekedam H, Dovlo D, Fitzgerald J, Habicht J, Harrison G, Kluge H, Lin V, Manabde N, Mirza Z, Saddiqi S, and Travis P. Strengthening health systems for universal health coverage and sustainable development. Bulletin of the World Health Organization. Published online 7 April 2017.
Wallace J, Pitts M, Liu C, Lin V, Hajarizadeh B, Richmond J, and Locarnini S. More than a virus: a qualitative study of the social implications of hepatitis B infection in China. International Journal for Equity in Health. 16, 2017: 137. DOI: 10.1186/s12939-017-0637-4.
Tan C, Baghirov R, Yap J, and Lin V. The challenge of making health services people-centred: how are policy-makers in Asia approaching it? International journal of integrated care. July 2017. 17(3):45. DOI: 10.5334/ijic.3157
Lin V, Baer B, and Silburn S. Towards the Sustainable Development Goals: implications for health systems in the Western Pacific. Journal of Korean Medical Association. August 2017. 60(8):632-639.
Bloom G, Buckland Merrett G, Wilkinson A, Lin V, and Paulin S. Antimicrobial resistance and universal health coverage. BMJ Global Health. 2017.
Percival N, O'Donoghue L, Lin V, Tsey K, Bailie R. Improving health promotion using quality improvement techniques in Australian Indigenous primary health care. In Frontiers in Public Health, 4:53. 2016. DOI: 10.3389/fpubh.2016.00053
Gleeson D, Dwyer J, Lin V, Legge D, and Hughes A. Can learning sets help policy managers with their wicked problems? Health Services Management Research. Available November 30, 2015 as DOI: 10.1177/0951484815616828.
Hughes A, Gleeson D, Legge D, and Lin V. Governance and policy capacity in health development and implementation in Australia. Politics and Society. Available 18 Nov 2015.
Lin V, Canaway R, Carter B, and Manderson L. Interface, interaction and integration: How people with chronic disease in Australia manage CAM and conventional medical services. Health Expectations. 29 JUL 2014, DOI: 10.1111/hex.12239.
Lin V and Carter B. Changing Health Problems and Health Systems: Challenges for Philanthropy in China in Ryan J, Chen L, and Saich T (Eds). Philanthropy for Health in China. Indiana University Press. 2014.
Shin AS, Kim HS, Lee KS, Lin V, and Liu C. Effect of diabetic case management intervention on health service utilization in Korea. International Journal of Nursing Practice. 06/2014; DOI: 10.1111/ijn.12348
Lin V. Universal health coverage and the public health workforce. Perspectives in Public Health. 2014; 134:245-247. DOI: 10.1177/1757913914546269
Lin, V., & Carter, B. From Healthy Public Policy to Intersectoral Action and Health in All Policies. In D. V. McQueen (Ed.), Global Handbook on Noncommunicable Diseases and Health Promotion (pp. 189-204). Dordrecht: Springer.2013.
Lin V, Canaway R, Carter B, and Manderson L. Room for Improvement: complementary therapy users and the Australian health system. Health Expectations. August 2013. DOI: 10.1111/hex.12125
Chong S, Lin V and Barraclough S. Rethinking HIV/AIDS programme evaluation: Lessons from Malaysia and the Philippines. Journal of International Development. 2013. DOI: 10.1002/jid.2980
Holden C and Lin V. Network structures and their relevance to the policy cycle: The National Male Health Policy of Australia as a case study. Social Science and Medicine, 74 (2), 2012.
Lin V. Transformations in the Healthcare System in China. Current Sociology. 60 (4) 2012.
Lin V and Fawkes S. People Centred Health Care: How might progress be monitored? International Journal of Person Centred Medicine. 2, 3, 2012: 593-600.
Lin V and Gillick D. Does workforce regulation have the intended effect? The case of Chinese Medicine practitioner registration. Australian Health Review. 35 (4), 2011.
Schang L, Lin V. Securing funds for health promotion: lessons from health promotion foundations based on experiences from Austria, Australia, Germany, Hungary and Switzerland. Health Promotion International. April 5, 2011. DOI: 10.1093/heapro/dar023
Lin V, Ridoutt L, Brink E, and Hollingsworth B. What incentives are effective for improving deployment of health workers in primary health care in Asia and the Pacific. In Jalilian H and Sen V. (Eds). Improving Health Sector Performance: Institutions, Motivations and Incentives: The Cambodia Dialogue. Institute for Southeast Asia Studies, Singapore. 2011.
J. Michael Sprafka MPH, PhD
Principal, Woodford Research Associates
J. Michael Sprafka MPH, PhD
Dr. Michael Sparfka is currently a Principal Consultant at Woodford Research Associate and applies his extensive expertise in pharmacovigilance, outcomes research and pharmacoeconomics to help some of the leading companies in the world.
Prior to Woodford Research Associates, Dr. Sprafka held many leadership roles in the industry as VP of Kendle Consulting, Executive Director of Center for Observational Research at Amgen, and Senior Director of Pharmacovigilance, Epidemiology and Pharmacoeconomics at Procter & Gamble.
Dr. Mike Sparfka received his Ph.D. of Epidemiology from the University of Minnesota, Minneapolis.
Education: University of Minnesota, Minneapolis, Minnesota
B.A., 1975; Biology
University of Minnesota, Minneapolis, Minnesota
M.S., 1980; Environmental Health
University of Minnesota, Minneapolis, Minnesota
M.P.H., 1982; Epidemiology
University of Minnesota, Minneapolis, Minnesota
Ph.D., 1986; Epidemiology
Professional Experience: Principal, Woodford Research Associates, 2018-
Executive Director, Center for Observational Research
Amgen, Inc 2011- 2018
Vice President, Kendle Consulting,
Kendle International 2009-2011
Senior Director, Pharmacovigilance, Epidemiology and
Pharmacoeconomics, Procter & Gamble, 1998 - 2009
Director, Epidemiology and Pharmacoeconomics
Procter & Gamble, 1994-1998
Associate Professor, University of Minnesota, Minneapolis, Minnesota, Division of Epidemiology, 1992-1994
Assistant Professor, University of Minnesota,
Minneapolis, Minnesota, Division of Epidemiology,
Epidemiologist, Minnesota Department of Health,
Minneapolis, Minnesota, 1981-1986
Research Fellow, University of Minnesota,
Minneapolis, Minnesota, Department of Epidemiology,
Research Assistant, University of Minnesota,
Minneapolis, Minnesota, Department of the Physical
Intern, Metropolitan Waste Control Commission,
St. Paul, Minnesota, 1978-1979
Research Assistant, University of Minnesota,
Minneapolis, Minnesota, 1978-1980
Chemical Lab Technician, General Mills, Inc.,
Minneapolis, Minnesota, 1977-1978
Medical Lab Technician, Petropolis, Brazil, 1976-1977
Summary: Epidemiologist with expertise in pharmacovigilance, outcomes research and pharmacoeconomices. Twenty-five years’ experience in leadership role of pharmacovigilance, epidemiology and pharmacoeconomic functions. Product categories include anti-infective, musculoskeletal, gastrointestinal, cardiovascular, neurological, inflammation, and women’s health.
Principal, Woodford Research Associates, LLC 2018-
Executive Director, Center for Observational Research, Amgen 2011-2018.
Responsible for the design and conduct of epidemiologic research in support of the therapeutic areas of musculoskeletal, inflammation and neurology. Chair of the Observational Research Review Group responsible for the technical oversight and review of all observational research conducted at Amgen. Led the streamlining of global SOPs, guidelines and templates to be consistent with pharmacoepidemiology best practices and EU Clinical Directive. Dotted line reporting to VP of Pharmacovigilance.
Vice President, Kendle Consulting, 2009-2011.
Led late phase development group and regulatory consulting and submissions. Management responsiblities for a global organization of 70 in US, UK, Germany, and Australia. Led the development and delivery of project proposals, bid defenses, and capabilities presentations for these functions. Provided scientific oversight of observational and post-marketing studies and consulting on study design strategies.
Senior Director Pharmacovigilance, Epidemiology and Pharmacoeconomics; P&G Pharmaceuticals 1998-2009
Responsible for the leadership of pharmacovigilance and risk management globally for both drugs in development and in the marketplace as well as the continued leadership of the epidemiology and pharmacoeconomic function (see below). Reorganized pharmacovigilance to insure single line of accountability globally. Assumed responsibility for the growth and development of approximately 40 pharmacovigilance personnel globally (i.e., US, Canada, UK, France, Germany, Spain). Led the implementation of global SOPs and pharmacovigilance best practices guidelines to establish and insure consistency in policies and procedures. Implemented temporary work assignment opportunities in different geographies for pharmacovigilance personnel to enhance understanding of the global regulatory environment and improve function effectiveness. Established and led the safety analysis group within pharmacovigilance to conduct all safety analyses for both marketed products and those in development. Established and led the risk management board, a cross-functional management team whose role is to direct product safety strategy. Led the world-wide labeling committee whose role is to recommend and implement product labeling changes (core label). Led the drafting and implementation of a risk management plan (RMP) that was accepted by the EMEA as part of the approval process for a drug in the Women’s Health category. Responsible person for the conduct and completion of all components of this RMP. Have final approval authority for all PSURs, CSSs, ad hoc safety reports, annual safety reports and the safety components of FDA Advisory meetings.
Director Epidemiology and Pharmacoeconomics; P&G Pharmaceuticals; 1994-1998
Responsible for the growth and development of this functional capacity within P&G pharmaceuticals. Provided epidemiologic support for other P&G businesses regarding potential safety signals (e.g., toxic shock/tampons, oral cancer/mouthwash, bladder cancer/hair dyes). Conducted first epidemiologic study of bisphosphonate therapy (etidronate) for osteoporosis to demonstrate safety and efficacy in real-world use. Presented findings to the Pharmaceutical Advertising Advisory Board (PAAB), formularies and thought leaders in support of commercialization efforts for claims, formulary positioning and thought leader acceptance of product safety and efficacy relative to competitor product. Implemented a line-item category in the R&D budget for functional services across all product categories including those in clinical development and in the market. Built an information system consisting of large administrative databases to enable the in-house conduct of safety and comparative effectiveness studies. Actively promoted the concept of clinical trials within cohorts to the clinical development organization as a means to better assess product safety. Hired, developed and promoted analysts, epidemiologists and economists (N=25) to conduct epidemiologic and economic work in support of the business.
Fellow, U.S.E.P.A., Assessment of Potential Health Risks Associated with Organic Contaminants in the Great Lakes Basin, 1978-1982
Epidemiologist, Centers for Disease Control Diabetes Control Project, Population-Based Epidemiologic Studies of Diabetes Mellitus in Minnesota, 1981-1986
Epidemiologist, Childhood Screening Legislative Task Force, Evaluation of Childhood Screening Programs in Minnesota, 1982-1983
Epidemiologist, Minnesota State Legislature, Feasibility of Full-Scale Epidemiologic Studies of Contaminated Drinking Water in St. Louis Park and New Brighton, Minnesota, 1984-1985
Co-Investigator, Minnesota Heart Health Program, NHLBI (R01 HL 25523). A primary goal of this research is to measure the contribution of changing lifestyles and medical care to the decline in coronary heart disease and stroke mortality rates. 1986-1994.
Co-Investigator, Minnesota Heart Survey, NHLBI (R01 HL 23727). This is a community based cardiovascular disease surveillance program that collects and interprets data on cardiovascular risk factors, hospitalization rates for MI's and strokes, medical care patterns and mortality rates with the goal of integrating these data to explain trends. 1986-1991.
Co-Investigator, Insulin C-Peptide, Youth, Age and Diabetes: Community Study, (NIH DK 33225), 1985-1994.
Co-Investigator, Longitudinal Study of CHD in Young Adults (CARDIA), NIH (N01 HC 48048). This is a multicenter collaborative research effort that collects and interprets data on cardiovascular risk factors in young adults. 1990-1994.
Co-Principal Investigator, A Colon Cancer Prevention Research Unit (CPRU), NIH (P01-CA50305). This is a program project assessing a variety of issues surrounding the etiology of colon cancer, including biomarkers of diet, etiology of adenomatous polyps, and effect of dietary involvement on polyp recurrence and statistical modeling of dietary patterns. 1990-1994.
Principal Investigator, Avoidable Mortality from Cancer in Native American Populations, NIH 1 U01 CA52267. This is an intervention program designed to identify Native American women at high risk for cervical cancer and improve compliance with standard medical practices and therapies. 1990-1994.
Co-Principal Investigator, Minnesota Heart Survey, NHLBI (R01 HL 23727). This is a community based cardiovascular disease surveillance program that collects and interprets data on cardiovascular risk factors, hospitalization rates for MI's and strokes, medical care patterns and mortality rates with the goal of integrating these data to explain trends. 1991-1994.
Principal Investigator, Family and Genetic Studies of Cardiovascular Disease - Field Center, NHLBI (NO1-HC-25105). This study is designed to identify and evaluate genetic and non-genetic determinants of cardiovascular disease and its risk factors. 1992-1994.
Teaching and Academic Administration
PubH 5330, Epidemiology I, W 1988, 1989, 1990; SSI 1989, 1990, 1991; F 1990;
F 1991; F 1992; Fall 1993
PubH 8379, Epidemiology Seminar, S 1988, 1989, 1990, 1991, 1992
Major Chair, Division of Epidemiology, University of Minnesota, 1987-1991
Director of Graduate Studies, Division of Epidemiology, University of Minnesota, 1991-1993
Faculty, AHA 10-Day U.S. Seminar on the Epidemiology and Prevention of Cardiovascular Diseases, 1989-1993. Tahoe City, CA.
Faculty, 10-Day International Seminar on the Epidemiology and Prevention of Cardiovascular Diseases, 1992 Rio de Janeiro, Brazil.
Selected Abstracts and Publications (from a total of 160)
Sprafka JM, Folsom AR, Burke GL, Edlavitch SA. Prevalence of coronary heart disease risk factors in an urban black population: The Minnesota Heart Survey, 1985. Preventive Medicine 1988;17:321-334.
Sprafka JM, Bender AP, Jagger HG: Prevalence of hypertension and associated risk factors among diabetic individuals. The Three-City Study. Diabetes Care 1988;11:17-22.
Sprafka JM, Folsom AR, Burke GL, Edlavitch SA. Prevalence of cardiovascular disease risk factors in blacks and whites: The Minnesota Heart Survey . Am J Public Health 1988; 78:1546-1549.
Sprafka JM, Burke GL, Folsom AR, Hahn LP. Hypercholesterolemia prevalence, awareness and treatment in blacks and whites: The Minnesota Heart Survey. Prev Med 1989;18:423-432.
Burke GL, Sprafka JM, Folsom AR, Luepker RV, Norsted SW, Blackburn H. Trends in coronary heart disease mortality, morbidity and risk factor levels from 1960 to 1986: The Minnesota Heart Survey. Int J Epidemiol 1989;18(Suppl 1):S73-S81.
Sprafka JM, Folsom AR, Burke GL, Hahn LP, Pirie P. Type A behavior measured by the Jenkins Activity Survey and its association with cardiovascular disease prevalence in blacks and whites: The Minnesota Heart Survey . J Behavioral Med 1990;13:1-13.
Sprafka JM, Fritsche TL, Baker R, Kurth D, Whipple D. Prevalence of undiagnosed eye disease in high risk diabetic individuals. Arch Int Med 1990;150:857-861.
Sprafka JM, Burke GL, Folsom AR, Luepker RV, Blackburn H. Continued decline in cardiovascular disease risk factors: results from the Minnesota Heart Survey, 1980-82 to 1985-87. Am J Epidemiol 1990;132:489-500.
Burke GL, Jacobs DR, Sprafka JM, Savage PJ, Sidney S, Wagenknecht LE. Obesity and overweight in young adults: The CARDIA Study. Prev Med 1990;19:476-488.
Sprafka JM, Strickland D, Gomez-Marin O, Prineas RJ. The effect of cuff size on blood pressure measurement in adults. Epidemiology 1991;2:215-217.
Sprafka JM, Burke GL, Folsom AR, McGovern PG, Hahn LP. Trends in the prevalence of diabetes mellitus in patients with myocardial infarction and the effect of diabetes on survival: The Minnesota Heart Survey. Diabetes Care 1991;14:537-543.
Sprafka JM, Norsted SW, Folsom AR, Burke GL, Luepker RV. Life-style factors do not explain racial differences in high density lipoprotein cholesterol: the Minnesota Heart Survey. Epidemiology 1992;3:156-163.
Sprafka JM, Xue S, Bushhouse SA, French LR, Martinez AM, Goetz FC. Cardiovascular disease risk factors and glucose tolerance: the Wadena City Health Study. Ann Epidemiol 1992;2:647-656.
Sellers TA, Sprafka JM, Rich SS, Potter JD, Ross JA, Nelson CL, Gapstur SM, Folsom AR. Does body fat distribution promote familial aggregation of adult-onset diabetes mellitus and postmenopausal breast cancer. Epidemiol 1994;5:102-108.
Higgins M, Province M, Heiss G, Eckfeldt J, Ellison RC, Folsom A, Rao DC, Sprafka JM, Williams R. The NHLBI family heart study: objectives and design. Am J Epidemiol 1996 143:1219-1228
Shapiro S, Castellana JV, Sprafka JM Alcohol-containing mouthwashes and oropharyngeal cancer: A spurious association due to underascertainment of confounders? Am J Epidemiol 1996;144:1091-1095
Collins JJ, Bukowski JA, Weed DL, Brent RL, Klein P, Boerstoel-Streefland M, Sprafka JM, Williams AL, Holsapple MP. Evaluating emerging issues in epidemiology. Reg Toxicol Pharmacol 2007 48:296-307.
Rizzoli R, Burlet N, Cahall D, Delmas PD, Eriksen EF, Felsenberg D, Grbic J, Jontell M, Landesberg R, Laslop A, Matton P, Papapoulos S, Sezer O, Sprafka JM, Reginster, JY Impact of osteonecrosis of the jaw on osteoporosis management: executive summary of an ESCEO and Foundation for Research on Osteoporosis and other Bone Diseases Working Group Meeting. Aging Health, 2007 3: 731-734.
Rizzoli R, Burlet N, Cahall D, Delmas PD, Eriksen EF, Felsenberg D, Grbic J, Jontell M, Landesberg R, Laslop A, Wollenhaupt M, Papapoulos S, Sezer O, Sprafka JM, Reginster, JY Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone, 2008; 42: 841-847.
Van Staa TJ, Sprafka JM. Study of adverse outcomes in women using testosterone therapy. Maturitas 2009;62:76-80.
Sietsema WK and Sprafka JM. Risk Management Principles for Devices and Pharmaceuticals: Global Perspectives on the Benefit: Risk Assessment of Medicinal Products. 2012., RAPS
Acquavella J, Bradbury B, Critchlow C, Sprafka J. Michael, Sullivan J, Litten JB. , Pharmacoepidemiology as Part of Pharmacovigilance for Biologic Therapies Mann’s Pharmacovigilance, Third Edition. Edited by Elizabeth B. Andrews and Nicholas Moore. © 2014 John Wiley & Sons, Ltd. Published 2014 by John Wiley & Sons, Ltd.
Grampp G., Bonafede M., Felix T., Li E., Malecki M., Sprafka J.M. Active and passive surveillance of enoxaparin generics: A case study relevant to biosimilars. Expert Opinion on Drug Safety. 2015;14: 349-360.
Xue F, Goli V, Petraro P, McMullan T, Sprafka JM, Tchetgen Tchetgen EJ. Marginal structural model to evaluate the association between cumulative osteoporosis medication and infection using claims data Osteoporos Int (2017) 28:2893-2901
Yusuf AA , Cummings SR, Watts NB, Tepie-Feudjo M, Sprafka JM, Zhou J, Guo H, Balasubramanian A, Cooper C. Real-world effectiveness of osteoporosis therapies for fracture reduction in post-menopausal women Archives of Osteoporosis (2018) 13:33
Sietsema WK and Sprafka JM. Risk Management Principles for Devices and Pharmaceuticals: Global Perspectives on the Benefit: Risk Assessment of Medicinal Products. Second Edition 2018., RAPS
Professional Organizations: Society for Epidemiologic Research, (1986-1994)
American Association of Public Health, (1984-1990)
Epidemiology Council, American Heart Association (1986-1994)
Associate Editor, Am. J. Epidemiology, (1993-1998)
International Society of Pharmacoepidemiology (current)
Head of USC U.S. - China Institute
Clayton Dube heads the USC U.S.-China Institute which focuses on the multidimensional and evolving U.S.-China relationship. Dube was trained as a historian, working on modern Chinese economic history. He lived in China for five years and has visited over fifty times for research, to lead delegations, or to lecture. Dube has long been committed to working to inform public discussion of U.S.-China ties. He was associate editor of the academic journal Modern China and editorial director for the online magazines AsiaMedia, Asia Pacific Arts, and US-China Today. He’s produced documentary films, including the institute’s twelve-part Assignment: China series on American reporting on China from the 1940s to today. Dube writes the institute’s Talking Points newsletter and is the author of several guides to teaching about China. He’s earned teaching awards at three universities.